http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0232936-A9
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_183de00a9122fbab96ec3a996c26991e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e51ab5d5fb373fc7645d76e2ad144e9d http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b31512cf2ce2bbb732d1cfb13e9d7739 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2799-026 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56905 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-44 |
| filingDate | 2001-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_605d18fc3ce934c6fa20d85c405a96f3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef3a1bfb825aad1e1954642127b271e2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_712eafc13cb5ee8d4b77ad061bf54e5a |
| publicationDate | 2002-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-0232936-A9 |
| titleOfInvention | E. histolytica-specific antibodies and clinical uses thereof |
| abstract | Invasive amoebiasis is caused by the pathogenic protozoa Entamoeba histolytica. E. histolytica is genetically distinct but morphologically identical to a nonpathogenic species Entamoeba dispar. Current methods for distinguishing between these species generally require the use of fresh, unpreserved stool specimens. This requirement limits their use in developed countries since the great majority of specimens are submitted preserved in stool fixative. This invention provides a method for generating monoclonal antibodies against the recombinant 170 kDa subunit of the Gal/GalNAc specific lectin of E. histolytica, that specifically recognize E. histolytica, but not E. dispar, in preserved stool samples. These antibodies do not cross-react with other bowel protozoa including Entamoeba coli, Giardia lamblia, and Dientamoeba fragilis. This invention also provides a method of expressing a functional recombinant 170 kDa subunit of the Gal/GalNAc specific lectin of E. histolyca and its cysteine-rich fragment in Spodoptera frugiperda cells infected by recombinant baculoviruses: The recombinant protein is used for developing improved vaccines and diagnostic tests. |
| priorityDate | 2000-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 136.